Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,901–2,000 of 4,108
Mesenchymal Stem Cell in Mice Uterine and Its Therapeutic Effect on Osteoporosis
Wang, Z., Wang, D., Liu, Y., Liu, D., Ren, Y., Liu, Z., Yu, B., Hao, M., & Xie, J. (2020) · Rejuvenation Research · doi:10.1089/rej.2019.2262 · Cited by 9
Leslie, W. D., Lix, L. M., & Binkley, N. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00775-8 · Cited by 9
Wattanachanya, L., & Pongchaiyakul, C. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001634 · Cited by 11
“5 or less, and patients who have had a history of low-trauma fracture are at high risk for fractures and will be candidates for antiosteoporotic medication.(3-6)”
BackgroundOptimizing DXA to Assess Skeletal Health: Key Concepts for Clinicians
Kennel, K. A., Sfeir, J. G., & Drake, M. T. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa632 · Cited by 11
Billington, E. O., Leslie, W. D., Brown, J. P., Prior, J. C., Morin, S. N., Kovács, C. S., Kaiser, S., Lentle, B. C., Anastassiades, T., Towheed, T., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05826-5 · Cited by 9
Arshad, A., Ibrahim, M., Arshad, H., bin Hammad, M., Sheikh, S. A., Khan, A. H., Jafri, L., & Nadeem, S. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00895-9 · Cited by 12
Keppler, A. M., Kraus, M., Blaschke, M., Thomasser, N., Kammerlander, C., Böcker, W., Neuerburg, C., & Stumpf, U. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040848 · Cited by 9
“Another 36 patients from the proximal femur group received no further DXA because osteoporosis was diagnosed according to the DVO guideline when certain aspects were present: low-energy trauma (fall from standing height, for example, after stumbling), X-rays show rarefied bone aspects, clinical signs of osteoporosis c…”
MethodNekooei, M., Shafiee, S. M., Zahiri, M., Maryamabadi, A., & Nabipour, I. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaa046 · Cited by 9
Ross, B. J., Lee, O. C., Harris, M. B., Dowd, T. C., Savoie, F. H., & Sherman, W. F. (2021) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-21-00185 · Cited by 13
Iki, M., Fujimori, K., Nakatoh, S., Tamaki, J., Ishii, S., Okimoto, N., Kamiya, K., & Ogawa, S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06265-y · Cited by 10
Flores, L. E., Kupzyk, K. A., Waltman, N. L., Beavers, K. M., & Bilek, L. D. (2022) · JCSM Rapid Communications · doi:10.1002/rco2.59 · Cited by 9
“All groups were supplemented with 1200 mg of calcium and 800–1000 IU of vitamin D3 per day, based on guidelines from the National Osteoporosis Foundation.21 Outcome measure assessment: dual-energy X-ray absorptiometry-acquired body composition All participants underwent DXA (Hologic QDR2000) scans at baseline, 6 month…”
MethodInfluentialPrescreening for osteoporosis with forearm bone densitometry in health examination population
Yue, C., Ding, N., Xu, L., Fu, Y., Guo, Y., Yang, Y., Zhao, X., & Sheng, Z. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05325-6 · Cited by 10
Identifying Causes of Fracture Beyond Bone Mineral Density: Evidence From Human Genetics
Lu, T., Forgetta, V., Greenwood, C. M. T., & Richards, J. B. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4632 · Cited by 15
“Pharmacological interventions are recommended for individuals with a high predicted probability of osteoporotic fracture.((5,10,11)) Currently, medications for preventing osteoporotic fracture include antiresorptive or anabolic medications.”
BackgroundFarshbaf‐Khalili, A., Ostadrahimi, A., Heris, J. A., et al. (2022) · Food Science & Nutrition · doi:10.1002/fsn3.3102 · Cited by 9
“According to the World Health Organization (WHO), osteoporosis is defined by a T- score below −2.5 and normal BMD by a T- score above −1.0 (Cosman et al., 2014; Prentice, 2004).”
BackgroundMethodInfluentialSu, Y., Wang, W., Liu, F., Cai, Y., Li, N., Li, H., Li, G., & Ma, L. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-998 · Cited by 9
“The treatment strategies for osteoporosis include lifestyle management and medication management (6).”
BackgroundT1 relaxation of bound and pore water in cortical bone
Ketsiri, T., Uppuganti, S., Harkins, K. D., Gochberg, D. F., Nyman, J. S., & Does, M. D. (2022) · NMR in Biomedicine · doi:10.1002/nbm.4878 · Cited by 10
“Osteoporosis is a worldwide health problem in which bone fractures lead to chronic pain, disability, and reduced life expectancy.(1) The standard”
Hassan, E. S., Maged, A. M., Kotb, A., Fouad, M. M., El‐Nassery, N., & Kamal, W. M. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002166 · Cited by 10
Substance P-Mediated Vascular Protection Ameliorates Bone Loss
Kim, D., Piao, J., Park, J. S., Lee, D., Hwang, D. Y., & Hong, H. S. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/9903336 · Cited by 10
“By age 80 years, women have lost, on average, approximately 30% of their peak bone mass [1, 2].”
Trends in Management of Osteoporosis Following Primary Vertebral Compression Fracture
Malacon, K. E., Beach, I. R., Touponse, G. C., Rangwalla, T., Lee, J. S., & Zygourakis, C. C. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad085 · Cited by 10
“Guidelines from the National Osteoporosis Foundation indicate that after a vertebral fracture, patients should start osteoporosis treatment to prevent subsequent fractures, as many pharmacological agents have been shown to reduce vertebral fracture risk within the first year of treatment [22-24].”
BackgroundGenetic influence on the association between bone mineral density and testosterone in Korean men
Shin, J., Sung, J., Lee, K. H., & Song, Y. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3298-4 · Cited by 10
Bone mineral density testing after fragility fracture: Informative test results likely.
Posen, J., Beaton, D., Sale, J. E. M., & Bogoch, E. R. (2013) · Canadian Family Physician · Cited by 18
Hip fracture history and risk of nonmelanoma skin cancer: a Danish population-based study
Lamberg, A. L., Olesen, & Jensen, A. Ø. (2011) · Clinical Epidemiology · doi:10.2147/clep.s25650 · Cited by 10
Pawłowska, M., Yang, Q., Hamata, B., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.329 · Cited by 9
Caldera, F., Saha, S., Wald, A. M., et al. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1169920 · Cited by 9
Ognjanovic, S. I., Μacut, D., Petakov, M. S., Kovačević, V. E., Isailovic, T. V., Antić, I. B., Ilic, D. S., Popovic, B. M., Bogavac, T., Pekmezovic, T. D., et al. (2016) · Journal of Medical Biochemistry · doi:10.1515/jomb-2016-0020 · Cited by 12
Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns
Habib, Z. A. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1256199 · Cited by 9
Maksimovic, M., Jurišić, V., Erdeljan, B., et al. (2017) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh160524041m · Cited by 9
Effect of acute pancreatitis on the risk of developing osteoporosis: A nationwide cohort study
Lin, S.-Y., Hsu, W., Lin, C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179358 · Cited by 9
Fracture Risk Assessment in Clinical Practice: Why Do It? What to Do It With?
Chandran, M. (2017) · Journal of clinical densitometry · doi:10.1016/j.jocd.2017.06.010 · Cited by 8
Binkley, N., Besuyen, R., Fuerst, T. P., Skillern, L., & Hans, D. B. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4258-y · Cited by 9
Referral pattern for DXA scanning in a tertiary care centre from southern India
Binu, A. J., Cherian, K. E., Kapoor, N., Thomas, N., & Paul, T. V. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0548-z · Cited by 9
Apalutamide: A new agent in the management of prostate cancer
May, M. B., & Glode, A. E. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219864424 · Cited by 10
“Although the SPARTAN and TITAN trials did not assess bone mineral density (BMD), it would be prudent to assess a patient’s BMD and risk for fracture prior to therapy initiation and periodically thereafter according to the aforementioned guidelines.(5,17,18) In addition, providers may consider intervention to reduce th…”
BackgroundMethodGuo, T., Xing, Y., Zhu, H.-Y., Yang, L., Liu, G., & Qiao, X. (2019) · Bioscience Reports · doi:10.1042/bsr20190432 · Cited by 11
RetractedZamoscinska, M., Faber, I. R., & Büsch, D. (2019) · Journal of Sport Rehabilitation · doi:10.1123/jsr.2019-0170 · Cited by 11
Xiao, W., He, J., Fu, W., Xu, Y., & Zhang, Z. (2020) · Gene · doi:10.1016/j.gene.2020.144543 · Cited by 8
Bisphosphonate utilization across the spectrum of eGFR
Titan, S., Laureati, P., Sang, Y., Chang, A. R., Evans, M., Trevisan, M., Levey, A. S., Grams, M. E., Inker, L. A., & Carrero, J. J. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0702-2 · Cited by 9
Amniotic fluid volume at 41 weeks and infant outcome.
Lam, H., Leung, W.-C., Lee, C.-P., & Lao, T. T.-H. (2006) · PubMed · Cited by 10
Kanis, J. А., Odén, A., Johansson, H., & McCloskey, E. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00068-6 · Cited by 11
Stimulating Effect of a Novel Synthesized Sulfonamido-Based Gallate ZXHA-TC on Primary Osteoblasts
Jin, P., Liao, L., Lin, X., et al. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2015.56.3.760 · Cited by 9
Chávez‐Valencia, V., Arce-Salinas, C. A., & Espinosa‐Ortega, F. (2014) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.12.001 · Cited by 9
Relationship between Bone Mineral Density and Physical Activity Level in the Elderly
Amiri, A. M., Hosseini, S. R., Farhad, R., et al. (2015) · Annals of Applied Sport Science · doi:10.18869/acadpub.aassjournal.3.2.23 · Cited by 9
The evolving role of zoledronic acid in early breast cancer
Gnant, M. (2009) · OncoTargets and Therapy · doi:10.2147/ott.s4082 · Cited by 9
Janković, T., Mikov, M., Zvekić-Svorcan, J., Minaković, I., Mikov, J., Bošković, K., & Mikić, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051901 · Cited by 10
“The final score is calculated by summing the scores obtained for each of the categories and dividing this value by the number of categories, resulting in the 0–3 range, where a higher figure indicates poorer quality of life [27].”
MethodTeam Approach: Bone Health Optimization in Orthopaedic Surgery
Pasqualini, I., Huffman, N., Keller, S. F., McLaughlin, J. P., Molloy, R. M., Deren, M. E., & Piuzzi, N. S. (2023) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00178 · Cited by 8
Nam, H., Han, J. W., Lee, S. K., Yang, H., Lee, H. L., Sung, P. S., Song, M. J., Kwon, J. H., Jang, J. W., Chang, U. I., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16593 · Cited by 10
Alissa, A., McDonnell, J. M., Ross, T. D., et al. (2024) · European Spine Journal · doi:10.1007/s00586-024-08307-5 · Cited by 8
Shirinezhad, A., Azarboo, A., Mafhoumi, A., Islampanah, M., Mohammadi, S., Raeini, A. G., & Hoveidaei, A. H. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01515-2 · Cited by 10
Liu, R., Fan, W., Hu, J., Xu, K., Huang, Z., Liu, Y., & Sun, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-88412-7 · Cited by 13
“These changes significantly increase susceptibility to fragility fractures, notably in regions such as the spine, hip, and wrist 1,2 .”
Wang, Z., Ma, G.-L., Xu, B., Chen, X., Yang, B., Qin, X., Duan, W.-L., Feng, M., Yin, H., Sun, K., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1506841 · Cited by 8
“It exhibits substantial variability, and existing standard diagnostic techniques often fall short of accurately identifying all individuals at risk of osteoporotic fractures and providing appropriate treatment (5, 6).”
How can theramechanics drive bone remodeling?
Allena, R., & Rémond, Y. (2025) · Mathematics and Mechanics of Complex Systems · doi:10.2140/memocs.2025.13.55 · Cited by 9
Wang, Y., Hu, H., & Huang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1615712 · Cited by 11
Frail phenotype might herald bone health worsening among end-stage renal disease patients
Chao, C., Huang, J., Chan, D., et al. (2017) · PeerJ · doi:10.7717/peerj.3542 · Cited by 8
Gómez‐Vaquero, C., Fábregas-Canales, D., Seoane‐Mato, D., Sánchez‐Piedra, C., Díaz‐González, F., Bustabad, S., Silva-Fernández, L., Sivera, F., Quilis, N., Blanco, F. J., et al. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.05.042 · Cited by 10
Grabel, Z. J., Lunati, M. P., Segal, D. N., et al. (2020) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2020.04.009 · Cited by 8
Promoting adherence to bone-loading exercises in postmenopausal women with low bone mass
Waltman, N. L., Cole, M. A., Kupzyk, K. A., Lappe, J. M., Mack, L. R., & Bilek, L. D. (2021) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000564 · Cited by 9
“To reduce their risk of osteoporosis, NOF recommends that postmenopausal women with low bone mass participate in weight-bearing activities with high boneloading forces and resistance training at least three times per week (Cosman et al., 2014).”
BackgroundPark, J. J., & Wong, C. (2022) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2022.151276 · Cited by 10
Gawęda, A. E., Lederer, E. D., & Brier, M. E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.807994 · Cited by 8
“Based on our prior experience in this area (1), we are confident that a new dosing tool could be developed, and we have developed the controller and have completed simulated clinical trials using this model.”
BackgroundMethodSharifi, F., Heydarzadeh, R., Vafa, R. G., Rahmani, M., Parizi, M. M., Ahmadi, A., Zamiri, B., Montaseri, M., & Kojuri, J. (2022) · Hypertension Research · doi:10.1038/s41440-022-00930-3 · Cited by 8
“Thus, they are now the first-line medication for these indications [14].”
BackgroundOsteoporosis identification among previously undiagnosed individuals with vertebral fractures
Gold, L. S., Cody, R. F., Tan, W. K., Marcum, Z. A., Meier, E. N., Sherman, K. J., James, K. T., Griffith, B. D., Avins, A. L., Kallmes, D. F., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06450-7 · Cited by 9
Initial evaluation in the climacteric: Number 5 - May 2022
Baccaro, L. F., Costa‐Paiva, L., Nasser, E. J., Valadares, A. L. R., da Silva, C. R., Nahás, E. A. P., Kulak, J., Rodrigues, M. A. H., Albernaz, M. A., Wender, M. C. O., et al. (2022) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0042-1750282 · Cited by 19
“As its diagnosis is essential to choose the appropriate therapy and reduce the risk of new fractures, thoracolumbar radiography is recommended for women with the characteristics described in Chart 5.(28)”
BackgroundThe Reciprocal Relationship between Osteoporosis and Renal Stones
Kim, S. Y., Chung, J., Park, D. S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226614 · Cited by 8
“3% in the general population and as high as 30% in postmenopausal women [4,5].”
BackgroundPositive relation between dietary inflammatory index and osteoporosis in postmenopausal women
Mohammadisima, N., Farshbaf‐Khalili, A., Ostadrahimi, A., & Pourmoradian, S. (2022) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000773 · Cited by 10
A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
Lake, J. E., Hyatt, A. N., Feng, H., Debroy, P., Kettelhut, A., Miao, H., Peng, L., Bhasin, S., Bell, S., Rianon, N. J., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad178 · Cited by 8
“HIV is a known risk factor for osteoporosis, and specific ART agents may also play a role [24].”
BackgroundArdebili, A. A., Fu, T. Y.-C., Dunnewold, N., Aghajafari, F., & Billington, E. O. (2023) · JBMR Plus · doi:10.1002/jbm4.10748 · Cited by 13
Screening for osteoporosis in people with MS: A new risk score
Zinganell, A., Hegen, H., Walde, J. F., Bauer, A., Berek, K., Barket, R., Auer, M., Bsteh, G., Donnemiller, E., Egger, A., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104726 · Cited by 10
Einspieler, H., Walter, C., Hacker, M., Karanikas, G., & Tamandl, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-50118-z · Cited by 9
“Bone mineral density (BMD) testing correlates with bone strength and therefore represents an excellent predictor of future fracture risk 17 .”
BackgroundWhole egg consumption in relation to bone health of the US population: a cross-sectional study
Shi, D., Liu, W., Hang, J., & Chen, W. (2024) · Food & Function · doi:10.1039/d3fo04248k · Cited by 8
Associations between ultra-distal forearm bone mineral density and incident fracture in women
Holloway‐Kew, K. L., Betson, A. G., Anderson, K. B., Kotowicz, M. A., & Pasco, J. A. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07041-4 · Cited by 9
“In categorical analyses, cutpoints of ≥ 20% and ≥ 3% were used for FRAX MOF and FRAX hip , respectively, according to US National Osteoporosis Foundation guidelines [12].”
MethodConditioned medium of human mesenchymal stem cells affects stem cell senescence in osteoporosis
Liu, K., Sakai, K., Watanabe, J., Dong, J., Maruyama, H., Li, X., & Hibi, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149858 · Cited by 8
FRAX-derived intervention and assessment thresholds for osteoporosis in ten Middle Eastern countries
Naseri, A., Bakhshayeshkaram, M., Salehi, S., Heydari, S. T., Dabbaghmanesh, M. H., & Dabbaghmanesh, M. M. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01397-0 · Cited by 9
“The assessment and management of fracture risk primarily depend on personal risk factors, the presence of fragility fractures, and Bone mineral density (BMD) measurements [5].”
Balkan, E. P., DENİZ, H. A., Kurt, M. H., et al. (2024) · European Annals of Dental Sciences · doi:10.52037/eads.2024.0008 · Cited by 8
Galchenko, A. V., Rizzo, G., Sidorova, E., Skliar, E., Baroni, L., Visaggi, P., Guidi, G., & de Bortoli, N. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1390773 · Cited by 12
Andreão, F. F., Borges, P., Palavani, L. B., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.07.127 · Cited by 8
Wang, G., Tan, J., Huang, C., Xu, Y., Yang, Z., & Huo, L. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907266 · Cited by 10
“Osteoporosis is a widespread skeletal issue characterized by reduced bone density, microstructural deterioration, and weakened bone strength, which escalates the risk of fractures [1].”
BackgroundWei, S., Pan, X., & Wei, J. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01698-y · Cited by 10
“Chronic hyper-glycemia has been observed to reduce osteoblast numbers, impair bone formation, slow bone mineralization, and enhance osteoclast activity, resulting in an imbalance in bone metabolism, particularly in elderly patients [2, 3].”
BackgroundOsteoporosis Treatment: An Evidence-Based Approach
Ragucci, K. R., & Shrader, S. P. (2011) · Journal of Gerontological Nursing · doi:10.3928/00989134-20110602-02 · Cited by 10
Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis
Murphy-Menezes, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.023 · Cited by 9
Bitto, A., Marini, H. R., Burnett, B. P., Polito, F., Levy, R. M., Irrera, N., Minutoli, L., Adamo, E. B., Squadrito, F., & Altavilla, D. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.02.003 · Cited by 8
Ioannidis, G., Kennedy, C. C., Dykeman, J., et al. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03914.x · Cited by 8
Welles, C. C., Schafer, A. L., Vittinghoff, E., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.007 · Cited by 8
National Utilization of Calcium Supplements in Patients with Osteoporotic Hip Fracture in Korea
Kim, S., Ko, Y.-B., Lee, Y., et al. (2013) · Journal of Bone Metabolism · doi:10.11005/jbm.2013.20.2.99 · Cited by 8
Development and validation of osteoporosis prescreening model for Iranian postmenopausal women
Matin, N., Tabatabaie, O., Keshtkar, A., et al. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0140-7 · Cited by 8
Toh, L. S., Lai, P. S. M., Othman, S. B., Wong, K. T., Low, B. Y., & Anderson, C. (2016) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2016.10.004 · Cited by 12
Nguyen, V. (2017) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000104 · Cited by 8
Lu, C., Chen, Y., Zhang, B., Chen, Y., Bai, F., & Chen, D. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s140900 · Cited by 8
Tung, C., Hsu, Y., Shih, Y., et al. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.12.011 · Cited by 8
Payumo, E., Cudal, B. I., & Crisostomo, T. D. (2018) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.033.02.13 · Cited by 8
Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting
Pleasants, R. A., Radlowski, P., & Davidson, H. E. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00680-x · Cited by 8
Kilpatrick, R. D., Chiuve, S. E., Leslie, W. D., Wegrzyn, L. R., Gao, W., Yang, H., Soliman, A. M., Snabes, M. C., Koenigsberg, S., Zhong, J., et al. (2020) · JBMR Plus · doi:10.1002/jbm4.10401 · Cited by 8
“The proportion of patients recommended to initiate antiosteoporosis treatment within the elagolix-treated group and the referent group was calculated using the following thresholds: 10-year probability of hip fracture ≥3% and 10-year probability of major osteoporotic fracture ≥20%.((29)) Table 1.”
MethodShirzadfar, H., & Gordoghli, N. (2020) · Recent Research in Endocrinology and Metabolic Disorder · doi:10.33702/rremd.2020.2.1.2 · Cited by 8
Hype um die Vitamin-D-Substitution: Was bleibt?
Bischoff-Ferrari, H. A. (2020) · Der Internist · doi:10.1007/s00108-020-00869-y · Cited by 11
Wang, C., Fu, S., Hung, C., Yang, R., Lin, J., Chen, H., Hsiao, F., & Shen, L. (2020) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2020.169 · Cited by 9
Osteoporosis health beliefs and self-efficacy among orthopedic nurses in Hunan Province, China
Dai, W., Peng, L., Xiong, Y., et al. (2020) · International Journal of Orthopaedic and Trauma Nursing · doi:10.1016/j.ijotn.2020.100839 · Cited by 8
Bone health and osteoporosis screening in gynecologic cancer survivors
Sobecki, J. N., Rice, L. W., & Hartenbach, E. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.11.028 · Cited by 10
Abaloparatide Real‐World Patient Experience Study
Gold, D. T., Weiss, R., Beckett, T., et al. (2021) · JBMR Plus · doi:10.1002/jbm4.10457 · Cited by 8
“], denosumab, estrogens, calcitonin) that reduce osteoclast bone resorption and thus prevent more bones from being broken down.((3)) Anabolic drugs, which can add bone and potentially improve bone microarchitecture, have become available as an additional treatment option.”
BackgroundPrevalence of osteoporosis and osteopenia assessed by densitometry in Japanese puerperal women
Kurabayashi, T., Nagai, K., Morikawa, K., Kamimura, N., Yanase, T., & Hayashi, K. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14694 · Cited by 11
“regardless of risk factors, and postmenopausal women above age 50 based on their risk factor profile.(23)”
BackgroundSchousboe, J. T., Langsetmo, L., Szulc, P., Lewis, J. R., Taylor, B. C., Kats, A. M., Vo, T., & Ensrud, K. E. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4257 · Cited by 8
“Current guidelines of the National Osteoporosis Foundation and International Society for Clinical Densitometry recommend targeted use of lateral spine imaging for subsets of the older male and female populations with a significant pre-test probability of prevalent vertebral fracture being present.((8,9)) The results o…”
BackgroundLocal delivery systems of morphogens/biomolecules in orthopedic surgical challenges
Roy, S., Mukherjee, P., Das, P. K., Ghosh, P. R., Datta, P., Kundu, B., & Nandi, S. K. (2021) · Materials Today Communications · doi:10.1016/j.mtcomm.2021.102424 · Cited by 10
The effect of SOX4 gene 3′UTR polymorphisms on osteoporosis
Guo, L., Gu, Z., He, Y., Wang, C., & Duan, J. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02454-x · Cited by 9
“The main pathogenesis of osteoporosis is the imbalance of osteoblastic bone formation and osteoclastic bone resorption resulting in the reduction of bone mass and the destruction of bone microstructure, thus increasing bone fragility and decreasing bone strength [4, 5].”
BackgroundGocho, Y., Tanaka, M., Sugawara, H., Furuhashi, M., Moniwa, N., Yamashita, T., Takizawa, H., Mukai, H., Ohno, K., Maeda, T., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02104-w · Cited by 9
“Therefore, vitamin D insufficiency has been evaluated by serum level of the 25(OH)D, but not by that of 1,25(OH)2D, in healthy subjects [6, 7].”
Background
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.